318 related articles for article (PubMed ID: 26784393)
1. PTD-fused p53 as a potential antiviral agent directly suppresses HBV transcription and expression.
Chu X; Wu B; Fan H; Hou J; Hao J; Hu J; Wang B; Liu G; Li C; Meng S
Antiviral Res; 2016 Mar; 127():41-9. PubMed ID: 26784393
[TBL] [Abstract][Full Text] [Related]
2. A peptide-based inhibitor of gp96 suppresses HBsAg expression and HBV replication by upregulation of p53.
Qian L; Fan H; Ju Y; Chen L; Li X; Ye X; Luo Y; Li C; Meng S
J Gen Virol; 2019 Aug; 100(8):1241-1252. PubMed ID: 31204972
[TBL] [Abstract][Full Text] [Related]
3. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication.
Kim HJ; Yoo HS; Kim JC; Park CS; Choi MS; Kim M; Choi H; Min JS; Kim YS; Yoon SW; Ahn JK
J Ethnopharmacol; 2009 Jul; 124(2):189-96. PubMed ID: 19409970
[TBL] [Abstract][Full Text] [Related]
4. Fusion protein of tapasin and hepatitis B core antigen 18‑27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice.
Tang Y; Chen X; Zhang Y; Tang Z; Zhuo M; Li D; Wang P; Zang G; Yu Y
Mol Med Rep; 2014 Apr; 9(4):1171-8. PubMed ID: 24535102
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo.
Lei YC; Hao YH; Zhang ZM; Tian YJ; Wang BJ; Yang Y; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Jul; 12(28):4492-7. PubMed ID: 16874860
[TBL] [Abstract][Full Text] [Related]
6. Intracellular-delivery of a single-chain antibody against hepatitis B core protein via cell-penetrating peptide inhibits hepatitis B virus replication in vitro.
Xun Y; Pan Q; Tang Z; Chen X; Yu Y; Xi M; Zang G
Int J Mol Med; 2013 Feb; 31(2):369-76. PubMed ID: 23241903
[TBL] [Abstract][Full Text] [Related]
7. KNK437 Inhibits Replication and Transcription of the Hepatitis B Virus.
Hu K; Huang Y; Mu J; Cheng Z; Zhu X
Bing Du Xue Bao; 2017 Jan; 33(1):24-35. PubMed ID: 30702818
[TBL] [Abstract][Full Text] [Related]
8. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
[TBL] [Abstract][Full Text] [Related]
9. Transbody against hepatitis B virus core protein inhibits hepatitis B virus replication in vitro.
Wang Y; Li Y; Li N; Zhu Q; Hui L; Liu X; Han Q; Lv Y; Wang Q; Yang G; Zhou Z; Liu Z
Int Immunopharmacol; 2015 Apr; 25(2):363-9. PubMed ID: 25676532
[TBL] [Abstract][Full Text] [Related]
10. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
11. IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B.
Lin SJ; Shu PY; Chang C; Ng AK; Hu CP
J Immunol; 2003 Nov; 171(9):4708-16. PubMed ID: 14568946
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro.
Korba BE; Gerin JL
Antiviral Res; 1995 Nov; 28(3):225-42. PubMed ID: 8629815
[TBL] [Abstract][Full Text] [Related]
13. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity.
Günther S; Paulij W; Meisel H; Will H
Virology; 1998 Apr; 244(1):146-60. PubMed ID: 9581787
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus is inhibited by RNA interference in cell culture and in mice.
Ying RS; Zhu C; Fan XG; Li N; Tian XF; Liu HB; Zhang BX
Antiviral Res; 2007 Jan; 73(1):24-30. PubMed ID: 16844238
[TBL] [Abstract][Full Text] [Related]
15. Transcription and replication of a natural hepatitis B virus nucleocapsid promoter variant is regulated in vivo by peroxisome proliferators.
Raney AK; Kline EF; Tang H; McLachlan A
Virology; 2001 Oct; 289(2):239-51. PubMed ID: 11689047
[TBL] [Abstract][Full Text] [Related]
16. Role of core protein mutations in the development of occult HBV infection.
Chen J; Liu B; Tang X; Zheng X; Lu J; Zhang L; Wang W; Candotti D; Fu Y; Allain JP; Li C; Li L; Li T
J Hepatol; 2021 Jun; 74(6):1303-1314. PubMed ID: 33453326
[TBL] [Abstract][Full Text] [Related]
17. [The fusion protein of cytoplasmic transduction peptide (CTP)-HBcAg18-27-Tapasin enhances specific immune response to hepatitis B virus and inhibits viral replication in transgenic mice].
Tang Y; Chen X; Zhou L; Zhuo M; Zang G; Tang Z; Yu Y
Zhonghua Gan Zang Bing Za Zhi; 2014 Jan; 22(1):24-9. PubMed ID: 24721239
[TBL] [Abstract][Full Text] [Related]
18. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
19. Specific anti-viral effects of RNA interference on replication and expression of hepatitis B virus in mice.
Wu Y; Huang AL; Tang N; Zhang BQ; Lu NF
Chin Med J (Engl); 2005 Aug; 118(16):1351-6. PubMed ID: 16157029
[TBL] [Abstract][Full Text] [Related]
20. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
